Item 16. Form 10-K Summary
11K characters. Original on sec.gov · Markdown
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | ||
| February 13, 2019 | By: | /s/ DAVID R. SMITH |
| David R. Smith | ||
| Corporate Executive Vice President and Chief Financial Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities indicated below and on the dates indicated.
| Signatures | Title | Date | |
| By: | /s/ JAMES C. FOSTER | Chairman, President and Chief Executive Officer | February 13, 2019 |
| James C. Foster | |||
| By: | /s/ DAVID R. SMITH | Corporate Executive Vice President and | February 13, 2019 |
| David R. Smith | Chief Financial Officer | ||
| By: | /s/ MICHAEL G. KNELL | Corporate Senior Vice President and | February 13, 2019 |
| Michael G. Knell | Chief Accounting Officer | ||
| By: | /s/ ROBERT J. BERTOLINI | Director | February 13, 2019 |
| Robert J. Bertolini | |||
| By: | /s/ STEPHEN D. CHUBB | Director | February 13, 2019 |
| Stephen D. Chubb | |||
| By: | /s/ DEBORAH T. KOCHEVAR | Director | February 13, 2019 |
| Deborah T. Kochevar | |||
| By: | /s/ MARTIN MACKAY | Director | February 13, 2019 |
| Martin Mackay | |||
| By: | /s/ JEAN-PAUL MANGEOLLE | Director | February 13, 2019 |
| Jean-Paul Mangeolle | |||
| By: | /s/ GEORGE E. MASSARO | Director | February 13, 2019 |
| George E. Massaro | |||
| By: | /s/ GEORGE M. MILNE, JR. | Director | February 13, 2019 |
| George M. Milne, Jr. | |||
| By: | /s/ C. RICHARD REESE | Director | February 13, 2019 |
| C. Richard Reese | |||
| By: | /s/ RICHARD F. WALLMAN | Director | February 13, 2019 |
| Richard F. Wallman |
EXHIBIT INDEX
| Exhibit No. | Description | Filed with this Form 10-K | Incorporation by Reference | ||
| Form | Filing Date | Exhibit No. | |||
| 10.20* | Separation Agreement between Davide Molho and Charles River Laboratories, Inc. dated August 1, 2018 (revised on August 28, 2018) | 10-Q | November 7, 2018 | 10.2 | |
| 10.21* | Consulting Agreement between Davide Molho and Charles River Laboratories, Inc. dated August 28, 2018 | 10-Q | November 7, 2018 | 10.3 | |
| 21.1 | Subsidiaries of Charles River Laboratories International, Inc. | X | |||
| 23.1 | Consent of PricewaterhouseCoopers LLP | X | |||
| 31.1 | Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer | X | |||
| 31.2 | Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer | X | |||
| 32.1 | Section 1350 Certification of the Chief Executive Officer and Chief Financial Officer | X | |||
| 101.INS | eXtensible Business Reporting Language (XBRL) Instance Document | X | |||
| 101.SCH | XBRL Taxonomy Extension Schema | X | |||
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase | X | |||
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase | X | |||
| 101.LAB | XBRL Taxonomy Extension Labels Linkbase | X | |||
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase | X | |||
| * Management contract or compensatory plan, contract or arrangement. | |||||
Previous: Item 15. (a)(1) and (2) Financial Statements and Schedules
Sponsor Sponsor this sector. One slot per industry, shown on every filing in it. Details